NCT03091192 2026-04-14Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT04579380 2025-12-19Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen Inc.Phase 2 Active not recruiting217 enrolled 19 charts